- Lung Cancer Basics
April 28, 2014 - As a member of the Patient Quality of Life Coalition (PQLC), Lung Cancer Alliance, along with 11 other advocacy groups, urged the Drug Enforcement Administration (DEA) against the rescheduling of Hydrocodone Combination Products (HCPs) from Schedule III to Schedule II. Moving a medication to a lower schedule is intended to curb misuse and abuse of the product. However, the coalition believes that rescheduling HCPs, which are commonly prescribed to treat pain in individuals with “…advanced, serious, and chronic illness,” would create an unintentional barrier to access to critical medication. The rescheduling of these medications would have adverse effects, such as a lack of availability at retail pharmacies, a decrease in the number of professionals who are authorized to prescribe such a drug and the widespread denials of refills for patients who desperately need it.